T-lymphocyte homing: An underappreciated yet critical hurdle for successful cancer immunotherapy

Laboratory Investigation

Volumn 97, Issue 6, 2017, Pages 669-697

  Sackstein, Robert ^a,b   Schatton, Tobias ^a,c,d   Barthel, Steven R ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CHEMOKINE RECEPTOR; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 7; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; RNA; SELECTIN; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 4; LYMPHOCYTE ANTIGEN RECEPTOR;

ARTICLE; BLOOD VESSEL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CAPILLARY ENDOTHELIAL CELL; CELL MIGRATION; CYTOTOXICITY; EFFECTOR CELL; FUCOSYLATION; GENE EDITING; HUMAN; IMMUNOLOGICAL MEMORY; LYMPH VESSEL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE HOMING; LYMPHOCYTE RECIRCULATION; LYMPHOCYTIC INFILTRATION; LYMPHOID TISSUE; MELANOMA; MELANOMA CELL; MEMORY T LYMPHOCYTE; METASTASIS; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; SOLID MALIGNANT NEOPLASM; STROMA CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TERTIARY LYMPHOID STRUCTURE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; VENULE; ANIMAL; BIOLOGICAL MODEL; CYTOLOGY; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; MEDICAL RESEARCH; MOUSE; NEOPLASMS; PHYSIOLOGY;

ANIMALS; BIOMEDICAL RESEARCH; HUMANS; IMMUNOTHERAPY; MICE; MICE, KNOCKOUT; MODELS, IMMUNOLOGICAL; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 85019771232     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2017.25     Document Type: Article

References (289)

1. Papaioannou NE, Beniata OV, Vitsos P, et al. Harnessing the immune system to improve cancer therapy. Ann Transl Med 2016;4:261.
2. Khalil DN, Smith EL, Brentjens RJ, et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 2016;13:273-290.
3. Houot R, Schultz LM, Marabelle A, et al. T-cell-based Immunotherapy: adoptive cell transfer and checkpoint inhibition. Cancer Immunol Res 2015;3:1115-1122.
4. Lee N, Zakka LR, Mihm Jr MC, et al. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology 2016;48:177-187.
5. Fu H, Ward EJ, Marelli-Berg FM. Mechanisms of T cell organotropism. Cell Mol Life Sci 2016;73:3009-3033.
6. Marelli-Berg FM, Cannella L, Dazzi F, et al. The highway code of T cell trafficking. J Pathol 2008;214:179-189.
7. Fu H, Wang A, Mauro C, et al. T lymphocyte trafficking: molecules and mechanisms. Front Biosci 2013;18:422-440.
8. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science 1998;282:1281-1284.
9. Peske JD, Woods AB, Engelhard VH. Control of CD8 T-cell infiltration into tumors by vasculature and microenvironment. Adv Cancer Res 2015;128:263-307.
10. Pardoll DM. The blockade of immune checkpoints in cancer immuno-therapy. Nat Rev Cancer 2012;12:252-264.
11. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27:450-461.
12. Buque A, Bloy N, Aranda F, et al. Trial watch: immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015;4:e1008814.
13. Kleffel S, Posch C, Barthel SR, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 2015;162:1242-1256.
14. Haanen JB, Baars A, Gomez R, et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 2006;55:451-458.
15. Pages F, Galon J, Dieu-Nosjean MC, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010;29:1093-1102.
16. Agace WW. T-cell recruitment to the intestinal mucosa. Trends Immunol 2008;29:514-522.
17. Gorfu G, Rivera-Nieves J, Ley K. Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med 2009;9:836-850.
18. Marsal J, Agace WW. Targeting T-cell migration in inflammatory bowel disease. J Intern Med 2012;272:411-429.
19. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97-110.
20. Wright N, Hidalgo A, Rodriguez-Frade JM, et al. The chemokine stromal cell-derived factor-1 alpha modulates alpha 4 beta 7 integrin-mediated lymphocyte adhesion to mucosal addressin cell adhesion molecule-1 and fibronectin. J Immunol 2002;168:5268-5277.
21. Heidemann J, Ogawa H, Rafiee P, et al. Mucosal angiogenesis regulation by CXCR4 and its ligand CXCL12 expressed by human intestinal microvascular endothelial cells. Am J Physiol Gastrointest Liver Physiol 2004;286:G1059-G1068.
22. Oyama T, Miura S, Watanabe C, et al. CXCL12 and CCL20 play a significant role in mucosal T-lymphocyte adherence to intestinal microvessels in mice. Microcirculation 2007;14:753-766.
23. de Paz JL, Moseman EA, Noti C, et al. Profiling heparin-chemokine interactions using synthetic tools. ACS Chem Biol 2007;2:735-744.
24. Ericsson A, Arya A, Agace W. CCL25 enhances CD103-mediated lymphocyte adhesion to E-cadherin. Ann N Y Acad Sci 2004;1029: 334-336.
25. Rivera-Nieves J, Olson T, Bamias G, et al. L-selectin, alpha 4 beta 1, and alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine. J Immunol 2005;174:2343-2352.
26. Apostolaki M, Manoloukos M, Roulis M, et al. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. Gastroenterology 2008; 134:2025-2035.
27. Bell LV, Else KJ. Mechanisms of leucocyte recruitment to the inflamed large intestine: redundancy in integrin and addressin usage. Parasite Immunol 2008;30:163-170.
28. Dogan A, MacDonald TT, Spencer J. Ontogeny and induction of adhesion molecule expression in human fetal intestine. Clin Exp Immunol 1993;91:532-537.
29. Girard JP, Moussion C, Forster R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol 2012;12: 762-773.
30. Miyasaka M, Tanaka T. Lymphocyte trafficking across high endothelial venules: dogmas and enigmas. Nat Rev Immunol 2004;4:360-370.
31. Rivera-Nieves J, Burcin TL, Olson TS, et al. Critical role of endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis. J Exp Med 2006;203:907-917.
32. Forster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 2008;8:362-371.
33. Bromley SK, Mempel TR, Luster AD. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 2008;9:970-980.
34. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 2014;32:659-702.
35. Shiow LR, Rosen DB, Brdickova N, et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 2006;440:540-544.
36. Cyster JG. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 1999;189:447-450.
37. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005;17: 326-332.
38. Sigmundsdottir H, Pan J, Debes GF, et al. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat Immunol 2007;8:285-293.
39. Denucci CC, Mitchell JS, Shimizu Y. Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there. Crit Rev Immunol 2009;29:87-109.
40. Barthel SR, Gavino JD, Descheny L, et al. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets 2007;11:1473-1491.
41. Lalor PF, Lai WK, Curbishley SM, et al. Human hepatic sinusoidal endothelial cells can be distinguished by expression of phenotypic markers related to their specialised functions in vivo. World J Gastroenterol 2006;12:5429-5439.
42. Chong BF, Murphy JE, Kupper TS, et al. E-selectin, thymus-and activation-regulated chemokine/CCL17, and intercellular adhesion molecule-1 are constitutively coexpressed in dermal microvessels: a foundation for a cutaneous immunosurveillance system. J Immunol 2004;172:1575-1581.
43. Sackstein R. The lymphocyte homing receptors: gatekeepers of the multistep paradigm. Curr Opin Hematol 2005;12:444-450.
44. Yakubenia S, Frommhold D, Scholch D, et al. Leukocyte trafficking in a mouse model for leukocyte adhesion deficiency II/congenital disorder of glycosylation IIc. Blood 2008;112:1472-1481.
45. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000;343:1020-1034.
46. Guarda G, Hons M, Soriano SF, et al. L-selectin-negative CCR7-effector and memory CD8+ T cells enter reactive lymph nodes and kill dendritic cells. Nat Immunol 2007;8:743-752.
47. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-763.
48. Harlin H, Meng Y, Peterson AC, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009;69:3077-3085.
49. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998;187:129-134.
50. Austrup F, Vestweber D, Borges E, et al. P-and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues. Nature 1997;385:81-83.
51. Sasaki K, Zhu X, Vasquez C, et al. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res 2007;67:6451-6458.
52. Sasaki K, Pardee AD, Qu Y, et al. IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. J Immunother 2009;32:793-802.
53. Burbach BJ, Medeiros RB, Mueller KL, et al. T-cell receptor signaling to integrins. Immunol Rev 2007;218:65-81.
54. Mirenda V, Jarmin SJ, David R, et al. Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28. Blood 2007;109:2968-2977.
55. van Kooyk Y, van de Wiel-van Kemenade P, Weder P, et al. Enhancement of LFA-1-mediated cell adhesion by triggering through CD2 or CD3 on T lymphocytes. Nature 1989;342:811-813.
56. Walch JM, Zeng Q, Li Q, et al. Cognate antigen directs CD8+ T cell migration to vascularized transplants. J Clin Invest 2013;123: 2663-2671.
57. Dustin ML, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 1989;341:619-624.
58. Raab M, Wang H, Lu Y, et al. T cell receptor "inside-out" pathway via signaling module SKAP1-RapL regulates T cell motility and interactions in lymph nodes. Immunity 2010;32:541-556.
59. Abram CL, Lowell CA. The ins and outs of leukocyte integrin signaling. Annu Rev Immunol 2009;27:339-362.
60. Shulman Z, Cohen SJ, Roediger B, et al. Transendothelial migration of lymphocytes mediated by intraendothelial vesicle stores rather than by extracellular chemokine depots. Nat Immunol 2012; 13:67-76.
61. Atarashi K, Hirata T, Matsumoto M, et al. Rolling of Th1 cells via P-selectin glycoprotein ligand-1 stimulates LFA-1-mediated cell binding to ICAM-1. J Immunol 2005;174:1424-1432.
62. Marelli-Berg FM, Jarmin SJ. Antigen presentation by the endothelium: a green light for antigen-specific T cell trafficking? Immunol Lett 2004;93:109-113.
63. Barthel SR, Schatton T. Homing in on the sweet side of immune checkpoint biology. Immunity 2016;44:1083-1085.
64. Yao L, Setiadi H, Xia L, et al. Divergent inducible expression of P-selectin and E-selectin in mice and primates. Blood 1999;94: 3820-3828.
65. Mondal N, Buffone Jr. A, Neelamegham S. Distinct glycosyltra-nsferases synthesize E-selectin ligands in human vs. mouse leukocytes. Cell Adh Migr 2013;7:288-292.
66. Carlsen HS, Haraldsen G, Brandtzaeg P, et al. Disparate lymphoid chemokine expression in mice and men: no evidence of CCL21 synthesis by human high endothelial venules. Blood 2005;106: 444-446.
67. Liu Z, Miner JJ, Yago T, et al. Differential regulation of human and murine P-selectin expression and function in vivo. J Exp Med 2010;207:2975-2987.
68. Khatib AM, Auguste P, Fallavollita L, et al. Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. Am J Pathol 2005;167:749-759.
69. Eichbaum C, Meyer AS, Wang N, et al. Breast cancer cell-derived cytokines, macrophages and cell adhesion: implications for metastasis. Anticancer Res 2011;31:3219-3227.
70. Pohlman TH, Stanness KA, Beatty PG, et al. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism. J Immunol 1986;136:4548-4553.
71. Messadi DV, Pober JS, Fiers W, et al. Induction of an activation antigen on postcapillary venular endothelium in human skin organ culture. J Immunol 1987;139:1557-1562.
72. Briscoe DM, Cotran RS, Pober JS. Effects of tumor necrosis factor, lipopolysaccharide, and IL-4 on the expression of vascular cell adhesion molecule-1 in vivo. Correlation with CD3+ T cell infiltration. J Immunol 1992;149:2954-2960.
73. Jacobs PP, Sackstein R. CD44 and HCELL: preventing hematogenous metastasis at step 1. FEBS Lett 2011;585:3148-3158.
74. Jiang M, Xu X, Bi Y, et al. Systemic inflammation promotes lung metastasis via E-selectin upregulation in mouse breast cancer model. Cancer Biol Ther 2014;15:789-796.
75. Hiratsuka S, Goel S, Kamoun WS, et al. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. Proc Natl Acad Sci USA 2011;108: 3725-3730.
76. Subramaniam M, Koedam JA, Wagner DD. Divergent fates of P-and E-selectins after their expression on the plasma membrane. Mol Biol Cell 1993;4:791-801.
77. Pan J, Xia L, McEver RP. Comparison of promoters for the murine and human P-selectin genes suggests species-specific and conserved mechanisms for transcriptional regulation in endothelial cells. J Biol Chem 1998;273:10058-10067.
78. Liu Z, Zhang N, Shao B, et al. Replacing the promoter of the murine gene encoding P-selectin with the human promoter confers humanlike basal and inducible expression in mice. J Biol Chem 2016;291: 1441-1447.
79. Soler D, Humphreys TL, Spinola SM, et al. CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood 2003;101: 1677-1682.
80. Reiss Y, Proudfoot AE, Power CA, et al. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 2001;194: 1541-1547.
81. Fuhlbrigge RC, Kieffer JD, Armerding D, et al. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997;389:978-981.
82. Fuhlbrigge RC, King SL, Sackstein R, et al. CD43 is a ligand for E-selectin on CLA+ human T cells. Blood 2006;107:1421-1426.
83. Matsumoto M, Atarashi K, Umemoto E, et al. CD43 functions as a ligand for E-Selectin on activated T cells. J Immunol 2005;175: 8042-8050.
84. Matsumoto M, Shigeta A, Furukawa Y, et al. CD43 collaborates with P-selectin glycoprotein ligand-1 to mediate E-selectin-depen-dent T cell migration into inflamed skin. J Immunol 2007;178: 2499-2506.
85. Alcaide P, King SL, Dimitroff CJ, et al. The 130-kDa glycoform of CD43 functions as an E-selectin ligand for activated Th1 cells in vitro and in delayed-type hypersensitivity reactions in vivo. J Invest Dermatol 2007;127:1964-1972.
86. Velazquez F, Grodecki-Pena A, Knapp A, et al. CD43 functions as an E-selectin ligand for Th17 cells in vitro and is required for rolling on the vascular endothelium and Th17 cell recruitment during inflammation in vivo. J Immunol 2016;196:1305-1316.
87. Picker LJ, Michie SA, Rott LS, et al. A unique phenotype of skin-associated lymphocytes in humans. Preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol 1990;136:1053-1068.
88. Adams DH, Hubscher SG, Fisher NC, et al. Expression of E-selectin and E-selectin ligands in human liver inflammation. Hepatology 1996;24: 533-538.
89. Adams DH, Yannelli JR, Newman W, et al. Adhesion of tumour-infiltrating lymphocytes to endothelium: a phenotypic and functional analysis. Br J Cancer 1997;75:1421-1431.
90. Schroeter MF, Ratsch BA, Lehmann J, et al. Differential regulation and impact of fucosyltransferase VII and core 2 beta1, 6-N-acetyl-glycosaminyltransferase for generation of E-selectin and P-selectin ligands in murine CD4+ T cells. Immunology 2012;137: 294-304.
91. Wagers AJ, Kansas GS. Potent induction of alpha(1, 3)-fucosyltran-sferase VII in activated CD4+ T cells by TGF-beta 1 through a p38 mitogen-activated protein kinase-dependent pathway. J Immunol 2000;165:5011-5016.
92. Nakayama F, Teraki Y, Kudo T, et al. Expression of cutaneous lymphocyte-associated antigen regulated by a set of glycosyltrans-ferases in human T cells: involvement of alpha1, 3-fucosyltransferase VII and beta1, 4-galactosyltransferase I. J Invest Dermatol 2000;115: 299-306.
93. Lim YC, Henault L, Wagers AJ, et al. Expression of functional selectin ligands on Th cells is differentially regulated by IL-12 and IL-4. J Immunol 1999;162:3193-3201.
94. Pink M, Ratsch BA, Mardahl M, et al. Imprinting of skin/inflammation homing in CD4+ T cells is controlled by DNA methylation within the fucosyltransferase 7 gene. J Immunol 2016;197:3406-3434.
95. Jiang X, Campbell JJ, Kupper TS. Embryonic trafficking of gammadelta T cells to skin is dependent on E/P selectin ligands and CCR4. Proc Natl Acad Sci USA 2010;107:7443-7448.
96. Medoff BD, Thomas SY, Luster AD. T cell trafficking in allergic asthma: the ins and outs. Annu Rev Immunol 2008;26:205-232.
97. Kunkel EJ, Campbell JJ, Haraldsen G, et al. Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med 2000;192: 761-768.
98. Papadakis KA, Prehn J, Nelson V, et al. The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol 2000;165: 5069-5076.
99. McNab G, Reeves JL, Salmi M, et al. Vascular adhesion protein 1 mediates binding of T cells to human hepatic endothelium. Gastroenterology 1996;110:522-528.
100. Galkina E, Thatte J, Dabak V, et al. Preferential migration of effector CD8+ T cells into the interstitium of the normal lung. J Clin Invest 2005;115:3473-3483.
101. Chen Q, Fisher DT, Clancy KA, et al. Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat Immunol 2006;7: 1299-1308.
102. Park CO, Kupper TS. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med 2015;21: 688-697.
103. Stark FC, Gurnani K, Sad S, et al. Lack of functional selectin ligand interactions compromises long term tumor protection by CD8+ T cells. PLoS One 2012;7:e32211.
104. Fisher DT, Chen Q, Skitzki JJ, et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest 2011;121:3846-3859.
105. Sasaki K, Zhao X, Pardee AD, et al. Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo. J Immunol 2008;181:104-108.
106. Tanaka Y, Mine S, Hanagiri T, et al. Constitutive up-regulation of integrin-mediated adhesion of tumor-infiltrating lymphocytes to osteoblasts and bone marrow-derived stromal cells. Cancer Res 1998;58:4138-4145.
107. Yoong KF, McNab G, Hubscher SG, et al. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol 1998;160:3978-3988.
108. Kitayama J, Nagawa H, Nakayama H, et al. Functional expression of beta1 and beta2 integrins on tumor infiltrating lymphocytes (TILs) in colorectal cancer. J Gastroenterol 1999;34:327-333.
109. Kitayama J, Tuno N, Nakayama H, et al. Functional down-regulation of beta1 and beta2 integrins of lamina propria lymphocytes (LPL) and tumor-infiltrating lymphocytes (TIL) in colorectal cancer patients. Ann Surg Oncol 1999;6:500-506.
110. Irjala H, Salmi M, Alanen K, et al. Vascular adhesion protein 1 mediates binding of immunotherapeutic effector cells to tumor endothelium. J Immunol 2001;166:6937-6943.
111. Weimann TK, Wagner C, Goos M, et al. CD44 variant isoform v10 is expressed on tumor-infiltrating lymphocytes and mediates hyaluronan-independent heterotypic cell-cell adhesion to melanoma cells. Exp Dermatol 2003;12:204-212.
112. Edwards S, Lalor PF, Tuncer C, et al. Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an alpha v beta3-independent manner. Br J Cancer 2006;95:1545-1554.
113. Markel G, Seidman R, Stern N, et al. Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carci-noembryonic cell adhesion molecule 1 interactions. J Immunol 2006;177:6062-6071.
114. Lee N, Barthel SR, Schatton T. Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking? Lab Invest 2014;94:13-30.
115. Robbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol 1996;8:628-636.
116. Henkart PA. Mechanism of lymphocyte-mediated cytotoxicity. Annu Rev Immunol 1985;3:31-58.
117. Anikeeva N, Sykulev Y. Mechanisms controlling granule-mediated cytolytic activity of cytotoxic T lymphocytes. Immunol Res 2011;51: 183-194.
118. Zeytun A, Hassuneh M, Nagarkatti M, et al. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. Blood 1997;90:1952-1959.
119. Hassin D, Garber OG, Meiraz A, et al. Cytotoxic T lymphocyte perforin and Fas ligand working in concert even when Fas ligand lytic action is still not detectable. Immunology 2011;133:190-196.
120. Bellone M, Calcinotto A. Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol 2013;3:231.
121. Sasaki K, Pardee AD, Okada H, et al. IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit. Eur J Immunol 2008;38:2865-2873.
122. Zinselmeyer BH, Heydari S, Sacristan C, et al. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med 2013;210:757-774.
123. Schneider H, Valk E, da Rocha Dias S, et al. CTLA-4 up-regulation of lymphocyte function-associated antigen 1 adhesion and clustering as an alternate basis for coreceptor function. Proc Natl Acad Sci USA 2005;102:12861-12866.
124. Ruocco MG, Pilones KA, Kawashima N, et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest 2012;122:3718-3730.
125. Angiari S, Donnarumma T, Rossi B, et al. TIM-1 glycoprotein binds the adhesion receptor P-selectin and mediates T cell trafficking during inflammation and autoimmunity. Immunity 2014;40:542-553.
126. Yang S, Liu F, Wang QJ, et al. The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes. PLoS One 2011;6:e22560.
127. Diaz-Montero CM, Zidan AA, Pallin MF, et al. Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L. Immunol Res 2013;57:23-33.
128. Tinoco R, Carrette F, Barraza ML, et al. PSGL-1 is an immune checkpoint regulator that promotes T cell exhaustion. Immunity 2016;44:1190-1203.
129. Fridman WH, Pages F, Sautes-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.
130. Mlecnik B, Tosolini M, Charoentong P, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010;138:1429-1440.
131. Mullins IM, Slingluff CL, Lee JK, et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004;64: 7697-7701.
132. Mikucki ME, Fisher DT, Matsuzaki J, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun 2015;6:7458.
133. Martinet L, Le Guellec S, Filleron T, et al. High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes. Oncoimmunology 2012;1:829-839.
134. Mule JJ, Custer M, Averbook B, et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther 1996;7:1545-1553.
135. Bedognetti D, Spivey TL, Zhao Y, et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer 2013;109:2412-2423.
136. Sapoznik S, Ortenberg R, Galore-Haskel G, et al. CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunol Immunother 2012;61:1833-1847.
137. Coppola D, Nebozhyn M, Khalil F, et al. Unique ectopic lymph nodelike structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol 2011;179: 37-45.
138. Messina JL, Fenstermacher DA, Eschrich S, et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2012;2:765.
139. Bennett LD, Fox JM, Signoret N. Mechanisms regulating chemokine receptor activity. Immunology 2011;134:246-256.
140. Sharma RK, Chheda Z, Jala VR, et al. Expression of leukotriene B(4) receptor-1 on CD8(+) T cells is required for their migration into tumors to elicit effective antitumor immunity. J Immunol 2013;191: 3462-3470.
141. Lund AW, Swartz MA. Role of lymphatic vessels in tumor immunity: passive conduits or active participants? J Mammary Gland Biol Neoplasia 2010;15:341-352.
142. Dudley AC. Tumor endothelial cells. Cold Spring Harb Perspect Med 2012;2:a006536.
143. Ager A, Watson HA, Wehenkel SC, et al. Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells. Biochem Soc Trans 2016;44:377-385.
144. Peske JD, Thompson ED, Gemta L, et al. Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat Commun 2015;6:7114.
145. Ager A, May MJ. Understanding high endothelial venules: lessons for cancer immunology. Oncoimmunology 2015;4:e1008791.
146. Martinet L, Garrido I, Filleron T, et al. Human solid tumors contain high endothelial venules: association with T-and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 2011;71:5678-5687.
147. Bussolati B, Deambrosis I, Russo S, et al. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003;17: 1159-1161.
148. Bussolati B, Grange C, Bruno S, et al. Neural-cell adhesion molecule (NCAM) expression by immature and tumor-derived endothelial cells favors cell organization into capillary-like structures. Exp Cell Res 2006;312:913-924.
149. Brenner W, Hempel G, Steinbach F, et al. Enhanced expression of ELAM-1 on endothelium of renal cell carcinoma compared to the corresponding normal renal tissue. Cancer Lett 1999;143:15-21.
150. Afanasiev OK, Nagase K, Simonson W, et al. Vascular E-selectin expression correlates with CD8 lymphocyte infiltration and improved outcome in Merkel cell carcinoma. J Invest Dermatol 2013;133: 2065-2073.
151. Garbi N, Arnold B, Gordon S, et al. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol 2004;172:5861-5869.
152. Lohr J, Ratliff T, Huppertz A, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin Cancer Res 2011;17:4296-4308.
153. Quezada SA, Peggs KS, Simpson TR, et al. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 2008;205:2125-2138.
154. Buckanovich RJ, Facciabene A, Kim S, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008;14:28-36.
155. Blank C, Brown I, Kacha AK, et al. ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo. J Immunol 2005;174:3416-3420.
156. Kuzu I, Bicknell R, Fletcher CD, et al. Expression of adhesion molecules on the endothelium of normal tissue vessels and vascular tumors. Lab Invest 1993;69:322-328.
157. Singh S, Ross SR, Acena M, et al. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med 1992;175:139-146.
158. Zhang B, Zhang Y, Bowerman NA, et al. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res 2008;68:1563-1571.
159. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015;348:74-80.
160. Motz GT, Santoro SP, Wang LP, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014;20:607-615.
161. Mulligan JK, Day TA, Gillespie MB, et al. Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. Hum Immunol 2009;70:375-382.
162. Wagner SC, Ichim TE, Ma H, et al. Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique? J Transl Med 2015; 13:340.
163. Berger R, Albelda SM, Berd D, et al. Expression of platelet-endothelial cell adhesion molecule-1 (PECAM-1) during melanoma-induced angiogenesis in vivo. J Cutan Pathol 1993;20:399-406.
164. Weishaupt C, Munoz KN, Buzney E, et al. T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin Cancer Res 2007;13:2549-2556.
165. Fukumura D, Salehi HA, Witwer B, et al. Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain. Cancer Res 1995;55: 4824-4829.
166. Bessa X, Elizalde JI, Mitjans F, et al. Leukocyte recruitment in colon cancer: role of cell adhesion molecules, nitric oxide, and transforming growth factor beta1. Gastroenterology 2002;122:1122-1132.
167. Griffioen AW, Damen CA, Martinotti S, et al. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 1996;56:1111-1117.
168. Piali L, Fichtel A, Terpe HJ, et al. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med 1995;181:811-816.
169. Dirkx AE, oude Egbrink MG, Castermans K, et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 2006;20:621-630.
170. Clark RA, Huang SJ, Murphy GF, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 2008;205:2221-2234.
171. Forster-Horvath C, Dome B, Paku S, et al. Loss of vascular adhesion protein-1 expression in intratumoral microvessels of human skin melanoma. Melanoma Res 2004;14:135-140.
172. Dirkx AE, Oude Egbrink MG, Kuijpers MJ, et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 2003;63: 2322-2329.
173. Wagner SC, Riordan NH, Ichim TE, et al. Safety of targeting tumor endothelial cell antigens. J Transl Med 2016;14:90.
174. Qiao L, Liang N, Zhang J, et al. Advanced research on vasculogenic mimicry in cancer. J Cell Mol Med 2015;19:315-326.
175. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999;155:739-752.
176. Frank NY, Schatton T, Kim S, et al. VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 2011;71:1474-1485.
177. Lund AW, Medler TR, Leachman SA, et al. Lymphatic vessels, inflammation, and immunity in skin cancer. Cancer Discov 2016;6:22-35.
178. Christiansen A, Detmar M. Lymphangiogenesis and cancer. Genes Cancer 2011;2:1146-1158.
179. Stacker SA, Williams SP, Karnezis T, et al. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer 2014;14: 159-172.
180. Yan J, Jiang Y, Ye M, et al. The clinical value of lymphatic vessel density, intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 expression in patients with oral tongue squamous cell carcinoma. J Cancer Res Ther 2014;10:C125-C130.
181. Reiser J, Banerjee A. Effector, memory, and dysfunctional CD8(+) T cell fates in the antitumor immune response. J Immunol Res 2016;2016: 8941260.
182. Marelli-Berg FM, Fu H, Vianello F, et al. Memory T-cell trafficking: new directions for busy commuters. Immunology 2010;130: 158-165.
183. Zhang Y, Ohkuri T, Wakita D, et al. Sialyl lewisx antigen-expressing human CD4+ T and CD8+ T cells as initial immune responders in memory phenotype subsets. J Leukoc Biol 2008;84:730-735.
184. Nolz JC, Starbeck-Miller GR, Harty JT. Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions. Immunotherapy 2011;3: 1223-1233.
185. Wu R, Forget MA, Chacon J, et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 2012;18:160-175.
186. Hadrup S, Donia M, Thor Straten P. Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron 2013;6:123-133.
187. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-1964.
188. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008;358:2698-2703.
189. Kim HJ, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res 2014;2:91-98.
190. Qi H. T follicular helper cells in space-time. Nat Rev Immunol 2016;16: 612-625.
191. Adeegbe DO, Nishikawa H. Natural and induced T regulatory cells in cancer. Front Immunol 2013;4:190.
192. Hoerning A, Koss K, Datta D, et al. Subsets of human CD4(+) regulatory T cells express the peripheral homing receptor CXCR3. Eur J Immunol 2011;41:2291-2302.
193. Abeynaike LD, Deane JA, Westhorpe CL, et al. Regulatory T cells dynamically regulate selectin ligand function during multiple challenge contact hypersensitivity. J Immunol 2014;193:4934-4944.
194. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013;14:e218-e228.
195. Sakaguchi S, Wing K, Onishi Y, et al. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009;21: 1105-1111.
196. Oelkrug C, Ramage JM. Enhancement of T cell recruitment and infiltration into tumours. Clin Exp Immunol 2014;178:1-8.
197. Bussard KM, Mutkus L, Stumpf K, et al. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res 2016;18:84.
198. Stover DG, Bierie B, Moses HL. A delicate balance: TGF-beta and the tumor microenvironment. J Cell Biochem 2007;101:851-861.
199. Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol 2015;15: 669-682.
200. Essand M, Loskog AS. Genetically engineered T cells for the treatment of cancer. J Intern Med 2013;273:166-181.
201. Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med 2016;22:26-36.
202. Dai H, Wang Y, Lu X, et al. Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst 2016;108:7.
203. Casucci M, Bondanza A. Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes. J Cancer 2011;2: 378-382.
204. Sampson JH, Choi BD, Sanchez-Perez L, et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 2014;20:972-984.
205. Chinnasamy D, Tran E, Yu Z, et al. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Cancer Res 2013;73:3371-3380.
206. Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010;330:827-830.
207. Lo A, Wang LC, Scholler J, et al. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res 2015;75:2800-2810.
208. Zhang H, Ye ZL, Yuan ZG, et al. New strategies for the treatment of solid tumors with CAR-T cells. Int J Biol Sci 2016;12:718-729.
209. Caruana I, Savoldo B, Hoyos V, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 2015;21:524-529.
210. Svane IM, Verdegaal EM. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? Cancer Immunol Immunother 2014;63:1081-1091.
211. Pockaj BA, Sherry RM, Wei JP, et al. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994;73:1731-1737.
212. Yeku OO, Brentjens RJ, Armored CAR. T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans 2016;44:412-418.
213. Hershkovitz L, Schachter J, Treves AJ, et al. Focus on adoptive T cell transfer trials in melanoma. Clin Dev Immunol 2010;2010:260267.
214. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188-195.
215. Caruso HG, Hurton LV, Najjar A, et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res 2015;75:3505-3518.
216. Liu X, Jiang S, Fang C, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Res 2015;75:3596-3607.
217. Budhu S, Loike JD, Pandolfi A, et al. CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med 2010;207:223-235.
218. Teng MW, Galon J, Fridman WH, et al. From mice to humans: developments in cancer immunoediting. J Clin Invest 2015;125: 3338-3346.
219. Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 2008;27: 5869-5885.
220. Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 2016;352:189-196.
221. Navai SA, Ahmed N. Targeting the tumour profile using broad spectrum chimaeric antigen receptor T-cells. Biochem Soc Trans 2016;44:391-396.
222. Wilkie S, van Schalkwyk MC, Hobbs S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 2012;32:1059-1070.
223. Peng W, Ye Y, Rabinovich BA, et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 2010;16: 5458-5468.
224. Idorn M, Thor Straten P, Svane IM, et al. Transfection of tumor-infiltrating T cells with mRNA encoding CXCR2. Methods Mol Biol 2016;1428:261-276.
225. Wagers AJ, Waters CM, Stoolman LM, et al. Interleukin 12 and interleukin 4 control T cell adhesion to endothelial selectins through opposite effects on alpha1, 3-fucosyltransferase VII gene expression. J Exp Med 1998;188:2225-2231.
226. Tsai AK, Davila E. Producer T cells: using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors. Oncoimmunology 2016;5:e1122158.
227. Zhang L, Morgan RA, Beane JD, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res 2015;21:2278-2288.
228. Koneru M, O'Cearbhaill R, Pendharkar S, et al. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med 2015;13:102.
229. Agarwala SS. The role of intralesional therapies in melanoma. Oncology 2016;30:436-441.
230. Roybal KT, Williams JZ, Morsut L, et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 2016;167:419-432 e416.
231. Morris EC, Stauss HJ. Optimizing T-cell receptor gene therapy for hematologic malignancies. Blood 2016;127:3305-3311.
232. Slaymaker IM, Gao L, Zetsche B, et al. Rationally engineered Cas9 nucleases with improved specificity. Science 2016;351:84-88.
233. Kleinstiver BP, Pattanayak V, Prew MS, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 2016;529:490-495.
234. Armerding D, Kupper TS. Functional cutaneous lymphocyte antigen can be induced in essentially all peripheral blood T lymphocytes. Int Arch Allergy Immunol 1999;119:212-222.
235. Ebel ME, Awe O, Kaplan MH, et al. Diverse inflammatory cytokines induce selectin ligand expression on murine CD4 T cells via p38alpha MAPK. J Immunol 2015;194:5781-5788.
236. Sackstein R. Glycosyltransferase-programmed stereosubstitution (GPS) to create HCELL: engineering a roadmap for cell migration. Immunol Rev 2009;230:51-74.
237. Merzaban JS, Burdick MM, Gadhoum SZ, et al. Analysis of glycoprotein E-selectin ligands on human and mouse marrow cells enriched for hematopoietic stem/progenitor cells. Blood 2011;118: 1774-1783.
238. Sackstein R, Merzaban JS, Cain DW, et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008;14:181-187.
239. Merzaban JS, Imitola J, Starossom SC, et al. Cell surface glycan engineering of neural stem cells augments neurotropism and improves recovery in a murine model of multiple sclerosis. Glycobiology 2015;25:1392-1409.
240. Parmar S, Liu X, Najjar A, et al. Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo. Blood 2015;125:1502-1506.
241. Dykstra B, Lee J, Mortensen LJ, et al. Glycoengineering of E-selectin ligands by intracellular versus extracellular fucosylation differentially affects osteotropism of human mesenchymal stem cells. Stem Cells 2016;34:2501-2511.
242. Crowley CA, Curnutte JT, Rosin RE, et al. An inherited abnormality of neutrophil adhesion. Its genetic transmission and its association with a missing protein. N Engl J Med 1980;302:1163-1168.
243. Arnaout MA, Pitt J, Cohen HJ, et al. Deficiency of a granulocyte-membrane glycoprotein (gp150) in a boy with recurrent bacterial infections. N Engl J Med 1982;306:693-699.
244. Anderson DC, Schmalsteig FC, Finegold MJ, et al. The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. J Infect Dis 1985;152:668-689.
245. Schwartz BR, Wayner EA, Carlos TM, et al. Identification of surface proteins mediating adherence of CD11/CD18-deficient lymphobl-astoid cells to cultured human endothelium. J Clin Invest 1990;85: 2019-2022.
246. Siegelman MH, Stanescu D, Estess P. The CD44-initiated pathway of T-cell extravasation uses VLA-4 but not LFA-1 for firm adhesion. J Clin Invest 2000;105:683-691.
247. Nandi A, Estess P, Siegelman M. Bimolecular complex between rolling and firm adhesion receptors required for cell arrest; CD44 association with VLA-4 in T cell extravasation. Immunity 2004;20:455-465.
248. Thankamony SP, Sackstein R. Enforced hematopoietic cell E-and L-selectin ligand (HCELL) expression primes transendothelial migration of human mesenchymal stem cells. Proc Natl Acad Sci USA 2011;108:2258-2263.
249. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-514.
250. Muthuswamy R, Berk E, Junecko BF, et al. NF-kappaB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res 2012;72:3735-3743.
251. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011;89:207-215.
252. Moncharmont C, Levy A, Guy JB, et al. Radiation-enhanced cell migration/invasion process: a review. Crit Rev Oncol Hematol 2014;92:133-142.
253. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
254. Moserle L, Casanovas O. Anti-angiogenesis and metastasis: a tumour and stromal cell alliance. J Intern Med 2013;273:128-137.
255. Steeg PS. Targeting metastasis. Nat Rev Cancer 2016;16:201-218.
256. Huang Y, Yuan J, Righi E, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA 2012;109:17561-17566.
257. Yu P, Lee Y, Liu W, et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005;201:779-791.
258. Gunda V, Frederick DT, Bernasconi MJ, et al. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression. Thyroid 2014;24:1241-1250.
259. Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, et al. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res 2010;34:899-905.
260. Wargo JA, Robbins PF, Li Y, et al. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol Immunother 2009;58:383-394.
261. Carlow DA, Corbel SY, Williams MJ, et al. IL-2,-4, and-15 differentially regulate O-glycan branching and P-selectin ligand formation in activated CD8 T cells. J Immunol 2001;167:6841-6848.
262. Pellegrini M, Calzascia T, Elford AR, et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med 2009;15:528-536.
263. Klebanoff CA, Finkelstein SE, Surman DR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 2004;101:1969-1974.
264. Epardaud M, Elpek KG, Rubinstein MP, et al. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 2008;68:2972-2983.
265. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol 2014;192:5451-5458.
266. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194:823-832.
267. Kline J, Brown IE, Zha YY, et al. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res 2008;14:3156-3167.
268. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005;8:369-380.
269. Cedeno-Laurent F, Barthel SR, Opperman MJ, et al. Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin-1 ligands and immune disease modulation. J Immunol 2010;185:4659-4672.
270. Cedeno-Laurent F, Opperman M, Barthel SR, et al. Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J Immunol 2012;188:3127-3137.
271. Cedeno-Laurent F, Opperman MJ, Barthel SR, et al. Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity. J Invest Dermatol 2012;132:410-420.
272. Barthel SR, Antonopoulos A, Cedeno-Laurent F, et al. Peracetylated 4-fluoro-glucosamine reduces the content and repertoire of N-and O-glycans without direct incorporation. J Biol Chem 2011;286: 21717-21731.
273. Yazawa EM, Geddes-Sweeney JE, Cedeno-Laurent F, et al. Melanoma cell galectin-1 ligands functionally correlate with malignant potential. J Invest Dermatol 2015;135:1849-1862.
274. Okwan-Duodu D, Pollack BP, Lawson D, et al. Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol 2015; 38:119-125.
275. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004;58:862-870.
276. Park SS, Dong H, Liu X, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 2015;3:610-619.
277. Larochelle C, Alvarez JI, Prat A. How do immune cells overcome the blood-brain barrier in multiple sclerosis? FEBS Lett 2011;585: 3770-3780.
278. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005;115: 1616-1626.
279. Koneru M, Monu N, Schaer D, et al. Defective adhesion in tumor infiltrating CD8+ T cells. J Immunol 2006;176:6103-6111.
280. Liao Y, Geng P, Tian Y, et al. Marked anti-tumor effects of CD8(+) CD62L(+) T cells from melanoma-bearing mice. Immunol Invest 2015;44:147-163.
281. Friedman KM, Prieto PA, Devillier LE, et al. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes. J Immunother 2012;35: 400-408.
282. Barthel SR, Hays DL, Yazawa EM, et al. Definition of molecular determinants of prostate cancer cell bone extravasation. Cancer Res 2013;73:942-952.
283. Sackstein R. The biology of CD44 and HCELL in hematopoiesis: the 'step 2-bypass pathway' and other emerging perspectives. Curr Opin Hematol 2011;18:239-248.
284. Yakubenko VP, Lishko VK, Lam SC, et al. A molecular basis for integrin alphaMbeta 2 ligand binding promiscuity. J Biol Chem 2002;277: 48635-48642.
285. Barthel SR, Johansson MW, McNamee DM, et al. Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma. J Leukoc Biol 2008;83:1-12.
286. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22.
287. Barthel SR, Jarjour NN, Mosher DF, et al. Dissection of the hyperadhesive phenotype of airway eosinophils in asthma. Am J Respir Cell Mol Biol 2006;35:378-386.
288. Barthel SR, Annis DS, Mosher DF, et al. Differential engagement of modules 1 and 4 of vascular cell adhesion molecule-1 (CD106) by integrins alpha4beta1 (CD49d/29) and alphaMbeta2 (CD11b/18) of eosinophils. J Biol Chem 2006;281:32175-32187.
289. Rohde D, Schluter-Wigger W, Mielke V, et al. Infiltration of both T cells and neutrophils in the skin is accompanied by the expression of endothelial leukocyte adhesion molecule-1 (ELAM-1): an immunohis-tochemical and ultrastructural study. J Invest Dermatol 1992;98: 794-799.